Elderly Sarcopenic Obesity
Conditions
Interventions
Experimental group:24 weeks of probiotic supplement treatment
Control group:Placebo
Sponsors
The Affiliated Hospital of Hangzhou Normal University
Eligibility
Sex/Gender
All
Age
60 Years to 84 Years
Inclusion criteria
Inclusion criteria: 1.Between 60-84 years old, gender is not limited. 2.Obesity criteria: BMI >=28 kg/m^2 or waist circumference >=90cm for men and >=85cm for women. 3.Meet the criteria for sarcopenia: use the diagnostic criteria for sarcopenia recommended by the 2019 AWGS: a. Determine the limb skeletal muscle mass index (SMI) using a body composition analyzer, with male SMI <7.0kg/m^2 for men and <5.7kg/m^2 for women;b. Grip strength <28kg for men and <18kg for women;and c. 6m step speed <1.0m/s. The diagnosis of sarcopenia can be made if the criteria of a, b or c are satisfied. 4.No alcohol intake and no use of any probiotic-related foods or drugs, antibiotics, hormones, or weight loss products in the last 3 months.
Exclusion criteria
Exclusion criteria: 1.Secondary obesity, including cortisolism, hypothyroidism, insulinoma, drug-derived obesity, etc; 2. With severe osteoarthritis or neurological tissue lesions and other lesions that impede motor function; 3.With serious lesions such as serious heart, lung, kidney, brain lesions and other serious systemic or infectious diseases, such as malignant tumors, serious heart and lung diseases, neurological disorders, psychiatric disorders, HIV infection, schistosomiasis or hepatic schistosomiasis, epilepsy, and other viral mixed infections; 4.Inability to complete bioimpedance testing due to the setting of a pacemaker, etc; 5. Subjects who are unlikely to comply with the protocol at the judgment of the investigator, patients with severe physical or psychological illnesses that may affect effectiveness or safety; 6.Patients who are unable to cooperate in completing the entire intervention and follow-up due to various other factors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Skeletal muscle index; | — |
Secondary
| Measure | Time frame |
|---|---|
| Indicators of glucose metabolism;Lipid metabolism indicators;Alteration intestinal flora; | — |
Countries
China
Contacts
Public ContactLuo Yan
The Affiliated Hospital of Hangzhou Normal University
Outcome results
None listed